scholarly journals Cancer risk among patients with multiple sclerosis: A population-based register study

2005 ◽  
Vol 118 (4) ◽  
pp. 979-984 ◽  
Author(s):  
Nete Munk Nielsen ◽  
Klaus Rostgaard ◽  
Søren Rasmussen ◽  
Nils Koch-Henriksen ◽  
Hans H. Storm ◽  
...  
2017 ◽  
Vol 19 (3) ◽  
pp. 435-446 ◽  
Author(s):  
Hanna Gyllensten ◽  
Michael Wiberg ◽  
Kristina Alexanderson ◽  
Anders Norlund ◽  
Emilie Friberg ◽  
...  

2015 ◽  
Vol 18 (7) ◽  
pp. A753-A754
Author(s):  
H Gyllensten ◽  
M Wiberg ◽  
P Tinghög ◽  
A Norlund ◽  
E Friberg ◽  
...  

2013 ◽  
Vol 21 (2) ◽  
pp. 238-244 ◽  
Author(s):  
L.-M. Sun ◽  
C.-L. Lin ◽  
C.-J. Chung ◽  
J.-A. Liang ◽  
F.-C. Sung ◽  
...  

Neurology ◽  
2020 ◽  
pp. 10.1212/WNL.0000000000011219
Author(s):  
Ruth Ann Marrie ◽  
Colleen Maxwell ◽  
Alyson Mahar ◽  
Okechukwu Ekuma ◽  
Chad McClintock ◽  
...  

Objective:To determine whether cancer risk differs in people with and without multiple sclerosis (MS), we compared incidence rates and cancer-specific mortality rates in MS and matched cohorts using population-based data sources.Methods:We conducted a retrospective matched cohort study using population-based administrative data from Manitoba and Ontario, Canada. We applied a validated case definition to identify MS cases, then selected 5 controls without MS matched on birth year, sex and region. We linked these cohorts to cancer registries, and estimated incidence of breast, colorectal and 13 other cancers. For breast and colorectal cancers, we constructed Cox models adjusting for age at the index date, area-level socioeconomic status, region, birth cohort year and comorbidity. We pooled findings across provinces using meta-analysis.Results:We included 53,984 MS cases and 266,920 controls. Multivariable analyses showed no difference in breast cancer risk (pooled hazard ratio [HR] 0.92 [95%CI: 0.78-1.09]) or colorectal cancer risk (pooled HR 0.83 [95%CI: 0.64-1.07]) between the cohorts. Mortality rates for breast and colorectal did not differ between cohorts. Bladder cancer incidence and mortality rates were higher among the MS cohort. Although the incidence of prostate, uterine and central nervous system cancers differed between the MS and matched cohorts, mortality rates did not.Conclusion:The incidence of breast and colorectal cancers does not differ between persons with and without MS; however, the incidence of bladder cancer is increased. Reported differences in the incidence of some cancers in the MS population may reflect ascertainment differences rather than true differences.


2015 ◽  
Vol 2015 ◽  
pp. 1-4
Author(s):  
Stergios Boussios ◽  
Vasiliki Kostadima ◽  
Anna Batistatou ◽  
Ioannis Tourkantonis ◽  
George Fotopoulos ◽  
...  

Multiple sclerosis (MS) is a chronic autoimmune disease that targets myelinated axons in the central nervous system (CNS). Cancer of unknown primary site (CUP) is a well-recognised clinical disorder, accounting for 3–5% of all malignant epithelial tumors. CUP is clinically characterised as an aggressive disease with early dissemination. Studies of cancer risk in MS patients have shown inconsistent findings. An increased risk of malignancy in patients with MS has been suggested, but recently serious questions have been raised regarding this association. Use of disease-modifying therapies might contribute to an increased cancer risk in selected MS patients. The concurrence of MS and CUP is exceptionally rare. Here we describe the case of a neuroendocrine carcinoma of unknown primary diagnosed in a male patient with a nine-year history of MS. The discussion includes data from all available population-based register studies with estimates of certain malignancies in patients with MS.


PLoS ONE ◽  
2014 ◽  
Vol 9 (8) ◽  
pp. e104165 ◽  
Author(s):  
Philip Brenner ◽  
Kristina Alexanderson ◽  
Charlotte Björkenstam ◽  
Jan Hillert ◽  
Jussi Jokinen ◽  
...  

2018 ◽  
Vol 68 ◽  
pp. S307-S308
Author(s):  
J. Söderholm ◽  
A. Yilmaz ◽  
K. Buesch ◽  
R. Wejstál ◽  
A. Brolund ◽  
...  

2021 ◽  
Vol 161 (2) ◽  
pp. 565-572
Author(s):  
Malene Skorstengaard ◽  
Maria Eiholm Frederiksen ◽  
Miguel Vázquez-Prada Baillet ◽  
Anna-Belle Beau ◽  
Pernille Tine Jensen ◽  
...  

2021 ◽  
pp. 135245852110196
Author(s):  
Jan Hillert ◽  
Jon A Tsai ◽  
Mona Nouhi ◽  
Anna Glaser ◽  
Tim Spelman

Background: Teriflunomide and dimethyl fumarate (DMF) are first-line disease-modifying treatments for multiple sclerosis with similar labels that are used in comparable populations. Objectives: The objective of this study was to compare the effectiveness and persistence of teriflunomide and DMF in a Swedish real-world setting. Methods: All relapsing-remitting multiple sclerosis (RRMS) patients in the Swedish MS registry initiating teriflunomide or DMF were included in the analysis. The primary endpoint was treatment persistence. Propensity score matching was used to adjust comparisons for baseline confounders. Results: A total of 353 teriflunomide patients were successfully matched to 353 DMF. There was no difference in the rate of overall treatment discontinuation by treatment group across the entire observation period (hazard ratio (HR) = 1.12; 95% confidence interval (CI) = 0.91–1.39; p = 0.277; reference = teriflunomide). Annualised relapse rate (ARR) was comparable ( p = 0.237) between DMF (0.07; 95% CI = 0.05–0.10) and teriflunomide (0.09; 95% CI = 0.07–0.12). There was no difference in time to first on-treatment relapse (HR = 0.78; 95% CI = 0.50–1.21), disability progression (HR = 0.55; 95% CI = 0.27–1.12) or confirmed improvement (HR = 1.17; 95% CI = 0.57–2.36). Conclusion: This population-based real-world study reports similarities in treatment persistence, clinical effectiveness and quality of life outcomes between teriflunomide and dimethyl fumarate.


Sign in / Sign up

Export Citation Format

Share Document